Zosano Pharma Corporation Company Profile (NASDAQ:ZSAN)

About Zosano Pharma Corporation (NASDAQ:ZSAN)

Zosano Pharma Corporation logoZosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company's short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ZSAN
  • CUSIP: N/A
  • Web: www.zosanopharma.com
Capitalization:
  • Market Cap: $38.02 million
  • Outstanding Shares: 39,230,000
Average Prices:
  • 50 Day Moving Avg: $0.95
  • 200 Day Moving Avg: $0.95
  • 52 Week Range: $0.45 - $3.54
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.26
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.56 per share
  • Price / Book: 1.71
Profitability:
  • EBIDTA: ($24,930,000.00)
  • Return on Equity: -172.90%
  • Return on Assets: -89.92%
Debt:
  • Current Ratio: 3.25%
  • Quick Ratio: 3.25%
Misc:
  • Average Volume: 859,986 shs.
  • Beta: 2.68
  • Short Ratio: 18.95
 

Frequently Asked Questions for Zosano Pharma Corporation (NASDAQ:ZSAN)

What is Zosano Pharma Corporation's stock symbol?

Zosano Pharma Corporation trades on the NASDAQ under the ticker symbol "ZSAN."

How were Zosano Pharma Corporation's earnings last quarter?

Zosano Pharma Corporation (NASDAQ:ZSAN) announced its earnings results on Thursday, August, 10th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.02. During the same quarter in the prior year, the company posted ($0.54) earnings per share. View Zosano Pharma Corporation's Earnings History.

When will Zosano Pharma Corporation make its next earnings announcement?

Zosano Pharma Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Zosano Pharma Corporation.

Where is Zosano Pharma Corporation's stock going? Where will Zosano Pharma Corporation's stock price be in 2017?

2 equities research analysts have issued 12-month price targets for Zosano Pharma Corporation's shares. Their predictions range from $3.00 to $4.00. On average, they expect Zosano Pharma Corporation's share price to reach $3.50 in the next twelve months. View Analyst Ratings for Zosano Pharma Corporation.

Who are some of Zosano Pharma Corporation's key competitors?

Who are Zosano Pharma Corporation's key executives?

Zosano Pharma Corporation's management team includes the folowing people:

  • John P. Walker, Chairman of the Board, President, Chief Executive Officer
  • Georgia L. Erbez, Interim Chief Financial Officer, Chief Business Officer
  • Eric Scharin, Vice President - Technical Operations
  • Thorsten von Stein M.D. Ph.D., Chief Medical Officer
  • Joseph P. Hagan, Director
  • Bruce D. Steel, Director
  • Troy E. Wilson Ph.D. J.D., Independent Director
  • Kleanthis G. Xanthopoulos Ph.D., Independent Director

When did Zosano Pharma Corporation IPO?

(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

Who owns Zosano Pharma Corporation stock?

Zosano Pharma Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (4.53%), Vanguard Group Inc. (3.11%), Nexthera Capital LP (1.07%), Victory Capital Management Inc. (0.60%), Granite Point Capital Management L.P. (0.38%) and Geneva Advisors LLC (0.26%). Company insiders that own Zosano Pharma Corporation stock include Donald J Kellerman, Enterprise Associates 12 New, Georgia Erbez, John Peter Walker, Konstantinos Alataris and M James Barrett. View Institutional Ownership Trends for Zosano Pharma Corporation.

Who sold Zosano Pharma Corporation stock? Who is selling Zosano Pharma Corporation stock?

Zosano Pharma Corporation's stock was sold by a variety of institutional investors in the last quarter, including Nexthera Capital LP and Victory Capital Management Inc.. View Insider Buying and Selling for Zosano Pharma Corporation.

Who bought Zosano Pharma Corporation stock? Who is buying Zosano Pharma Corporation stock?

Zosano Pharma Corporation's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Northern Trust Corp. Company insiders that have bought Zosano Pharma Corporation stock in the last two years include Donald J Kellerman, Georgia Erbez, John Peter Walker and Konstantinos Alataris. View Insider Buying and Selling for Zosano Pharma Corporation.

How do I buy Zosano Pharma Corporation stock?

Shares of Zosano Pharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zosano Pharma Corporation's stock price today?

One share of Zosano Pharma Corporation stock can currently be purchased for approximately $0.96.


MarketBeat Community Rating for Zosano Pharma Corporation (NASDAQ ZSAN)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  120
MarketBeat's community ratings are surveys of what our community members think about Zosano Pharma Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Zosano Pharma Corporation (NASDAQ:ZSAN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (266.11% upside)

Analysts' Ratings History for Zosano Pharma Corporation (NASDAQ:ZSAN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/24/2017Piper Jaffray CompaniesInitiated CoverageOverweight$4.00LowView Rating Details
3/11/2017Roth CapitalSet Price TargetBuy$3.00MediumView Rating Details
8/11/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Zosano Pharma Corporation (NASDAQ:ZSAN)
Earnings by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)
Earnings History by Quarter for Zosano Pharma Corporation (NASDAQ ZSAN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.15)N/AView Earnings Details
8/10/2017Q2 2017($0.15)($0.17)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.30)($0.34)ViewListenView Earnings Details
3/1/2017Q4 2016($0.45)($0.46)ViewN/AView Earnings Details
8/10/2016Q2($0.50)($0.54)ViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.68)ViewListenView Earnings Details
3/29/2016Q4($0.67)($0.64)ViewListenView Earnings Details
11/9/2015Q315($0.61)($0.72)$380.00 millionViewN/AView Earnings Details
8/12/2015Q215($0.53)($0.63)$0.22 million$0.10 millionViewN/AView Earnings Details
3/25/2015($0.64)($1.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zosano Pharma Corporation (NASDAQ:ZSAN)
2017 EPS Consensus Estimate: ($1.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.43)($0.43)($0.43)
Q2 20171($0.18)($0.18)($0.18)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.24)($0.24)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zosano Pharma Corporation (NASDAQ:ZSAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zosano Pharma Corporation (NASDAQ:ZSAN)
Insider Ownership Percentage: 2.95%
Institutional Ownership Percentage: 22.66%
Insider Trades by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)
Institutional Ownership by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)
Insider Trades by Quarter for Zosano Pharma Corporation (NASDAQ:ZSAN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017Georgia ErbezCFOBuy68,000$1.32$89,760.00View SEC Filing  
5/25/2017John Peter WalkerCEOBuy73,716$1.36$100,253.76View SEC Filing  
2/13/2017Enterprise Associates 12 NewMajor ShareholderSell1,099,996$2.01$2,210,991.96View SEC Filing  
9/16/2016Enterprise Associates 12 NewMajor ShareholderSell7,471$0.75$5,603.25View SEC Filing  
9/13/2016Enterprise Associates 12 NewMajor ShareholderSell10,000$0.74$7,400.00View SEC Filing  
8/29/2016M James BarrettMajor ShareholderSell50,000$1.01$50,500.00View SEC Filing  
8/24/2016Enterprise Associates 12 NewMajor ShareholderSell1,200$1.21$1,452.00View SEC Filing  
8/19/2016Donald J KellermanVPBuy15,920$1.32$21,014.40View SEC Filing  
8/19/2016Georgia ErbezCFOBuy47,750$1.32$63,030.00View SEC Filing  
8/19/2016John Peter WalkerDirectorBuy63,700$1.32$84,084.00View SEC Filing  
8/19/2016Konstantinos AlatarisCEOBuy127,389$1.32$168,153.48View SEC Filing  
7/21/2016Enterprise Associates 12 NewMajor ShareholderSell23,681$1.27$30,074.87View SEC Filing  
7/13/2016Enterprise Associates 12 NewMajor ShareholderSell13,382$1.20$16,058.40View SEC Filing  
1/30/2015Enterprise Associates 12 NewMajor ShareholderBuy23,457$11.00$258,027.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Zosano Pharma Corporation (NASDAQ:ZSAN)
Latest Headlines for Zosano Pharma Corporation (NASDAQ:ZSAN)
Source:
DateHeadline
finance.yahoo.com logoZosano Presents Data from ZOTRIP Study at International Headache Society
finance.yahoo.com - September 14 at 12:11 PM
finance.yahoo.com logoZosano Pharma Announces US Patent Office Publication of “Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines”
finance.yahoo.com - August 29 at 10:08 AM
americanbankingnews.com logo Analysts Expect Zosano Pharma Corporation (ZSAN) to Announce -$0.15 EPS
www.americanbankingnews.com - August 25 at 4:10 AM
seekingalpha.com logoZosano Pharma's (ZSAN) CEO John Walker on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 12 at 9:06 AM
americanbankingnews.com logoZosano Pharma Corporation (ZSAN) vs. Acorda Therapeutics (ACOR) Head to Head Comparison
www.americanbankingnews.com - August 11 at 4:58 PM
globenewswire.com logoZosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update
globenewswire.com - August 11 at 9:24 AM
finance.yahoo.com logoZosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update
finance.yahoo.com - August 11 at 9:24 AM
americanbankingnews.com logoZosano Pharma Corporation (ZSAN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - August 10 at 6:21 PM
globenewswire.com logoZosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update - GlobeNewswire (press release)
globenewswire.com - August 4 at 10:21 AM
nasdaq.com logoZosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update - Nasdaq
www.nasdaq.com - August 2 at 9:02 AM
finance.yahoo.com logoZosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update
finance.yahoo.com - August 2 at 9:02 AM
streetinsider.com logoZosano Pharma (ZSAN) Announces Positive Phase 1 Data of Zolmitriptan Delivery - StreetInsider.com
www.streetinsider.com - August 1 at 8:08 AM
finance.yahoo.com logoZosano Announces Publication of Positive Phase 1 Data of Zolmitriptan Delivery In Future Medicine’s Pain Management Journal
finance.yahoo.com - August 1 at 8:08 AM
americanbankingnews.com logoZosano Pharma Corporation (ZSAN) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
seekingalpha.com logoROTY Edition 1 Volume 11: Our First Sell - Seeking Alpha
seekingalpha.com - July 13 at 8:40 PM
streetinsider.com logoZosano Pharma (ZSAN) Reports Outcome of End of Phase 2 Meetings with FDA - StreetInsider.com
www.streetinsider.com - June 27 at 9:35 AM
finance.yahoo.com logoZosano Pharma Announces Outcome of End of Phase 2 Meetings with FDA
finance.yahoo.com - June 27 at 9:35 AM
americanbankingnews.com logoComparing Zosano Pharma Corporation (ZSAN) and GW Pharmaceuticals PLC (GWPH)
www.americanbankingnews.com - June 24 at 12:14 PM
americanbankingnews.com logo Analysts Expect Zosano Pharma Corporation (ZSAN) Will Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - June 21 at 12:08 PM
globenewswire.com logoZosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
www.globenewswire.com - June 14 at 4:32 PM
finance.yahoo.com logoZosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - June 14 at 4:32 PM
streetinsider.com logoZosano Pharma (ZSAN) Presents Additional Data from ZOTRIP Study - StreetInsider.com
www.streetinsider.com - June 12 at 3:16 PM
finance.yahoo.com logoZosano Presents Additional Data from ZOTRIP Study at American Headache Society, Demonstrating Positive Results for Pain Freedom and Sustained Pain Freedom
finance.yahoo.com - June 12 at 3:16 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - June 6 at 6:16 PM
globenewswire.com logoZosano to Present Migraine Data at Three Industry-Leading Conferences - GlobeNewswire (press release)
globenewswire.com - June 2 at 8:18 AM
finance.yahoo.com logoZosano to Present Migraine Data at Three Industry-Leading Conferences
finance.yahoo.com - June 2 at 8:18 AM
finance.yahoo.com logoZosano Pharma Corp (ZSAN) Interim CEO John Peter Walker Bought $100,254 of Shares
finance.yahoo.com - May 27 at 6:58 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - May 26 at 8:55 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) CFO Purchases $89,760.00 in Stock
www.americanbankingnews.com - May 25 at 10:21 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) CEO Acquires $100,253.76 in Stock
www.americanbankingnews.com - May 25 at 10:21 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Announces Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - May 10 at 5:18 PM
prnewswire.com logoBiotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics - PR Newswire (press release)
www.prnewswire.com - May 10 at 8:45 AM
streetinsider.com logoZosano Pharma (ZSAN) Reports Q4 Loss of $0.34; CEO Resigns
www.streetinsider.com - May 9 at 9:00 PM
finance.yahoo.com logoInvestor Network: Zosano Pharma Corp. to Host Earnings Call
finance.yahoo.com - May 9 at 9:00 PM
finance.yahoo.com logoZosano Reports First Quarter 2017 Financial Results and Announces Management Changes
finance.yahoo.com - May 9 at 9:00 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 8 at 9:00 AM
feeds.benzinga.com logoZosano Pharma to Host Conference Call on First Quarter 2017 Financial Results and Provide Operational Update
feeds.benzinga.com - May 8 at 5:43 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Earns Media Impact Rating of -0.12
www.americanbankingnews.com - May 4 at 8:20 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Expected to Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - May 3 at 12:04 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Getting Somewhat Critical News Coverage, Study Finds
www.americanbankingnews.com - April 29 at 9:16 AM
americanbankingnews.com logoShort Interest in Zosano Pharma Corp (ZSAN) Grows By 35.1%
www.americanbankingnews.com - April 29 at 1:17 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Getting Somewhat Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 25 at 3:11 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Receiving Somewhat Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 20 at 9:17 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Earns Daily Coverage Optimism Rating of -0.10
www.americanbankingnews.com - April 16 at 8:48 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Earning Somewhat Negative News Coverage, Analysis Finds
www.americanbankingnews.com - April 13 at 9:21 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Short Interest Down 12.5% in March
www.americanbankingnews.com - April 12 at 7:17 AM
americanbankingnews.com logo Analysts Anticipate Zosano Pharma Corp (ZSAN) Will Post Earnings of -$0.30 Per Share
www.americanbankingnews.com - April 11 at 6:07 PM
finance.yahoo.com logoShkreli Gives Zosano a Giant Headache
finance.yahoo.com - April 7 at 1:41 PM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Receives New Coverage from Analysts at Piper Jaffray Companies
www.americanbankingnews.com - March 30 at 8:23 AM
americanbankingnews.com logoZosano Pharma Corp (ZSAN) Short Interest Update
www.americanbankingnews.com - March 28 at 7:07 AM

Social

Chart

Zosano Pharma Corporation (ZSAN) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff